» Articles » PMID: 29263658

Smoking History and Emphysema in Asthma-COPD Overlap

Overview
Publisher Dove Medical Press
Specialty Pulmonary Medicine
Date 2017 Dec 22
PMID 29263658
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Emphysema is a distinct feature for classifying COPD, and smoking history (≥10 pack-years) is one of several newly proposed criteria for asthma-COPD overlap (ACO). We studied whether or not a smoking history (≥10 pack-years) and emphysema are useful markers for classifying ACO and differentiating it from asthma with chronic airflow obstruction (CAO).

Methods: We retrospectively studied the mortalities and frequencies of exacerbation in 256 consecutive patients with ACO (161 with emphysema and 95 without emphysema) who had ≥10 pack-years smoking history, 64 asthma patients with CAO but less of a smoking history (<10 pack-years) and 537 consecutive patients with COPD (452 with emphysema and 85 without emphysema) from 2000 to 2016. In the patients with emergent admission, the causes were classified into COPD exacerbation, asthma attack, and others.

Results: No asthma patients with CAO had emphysema according to computed tomography findings. The prognoses were significantly better in patients with asthma and CAO than in those with ACO and COPD and better in those with ACO than in those with COPD. In both ACO and COPD patients, the prognoses were better in patients without emphysema than in those with it (=0.027 and =0.023, respectively). The frequencies of emergent admission were higher in COPD patients than in ACO patients, and higher in patients with emphysema than in patients without emphysema. ACO/emphysema (+) patients experienced more frequent admission due to COPD exacerbation (<0.001), while ACO/emphysema (-) patients experienced more frequent admission due to asthma attack (=0.014).

Conclusion: A smoking history (≥10 pack-years) was found to be a useful marker for differentiating ACO and asthma with CAO, and emphysema was a useful marker for classifying ACO. These markers are useful for predicting the overall survival and frequency of exacerbation.

Citing Articles

The Influence of Emphysema on Treatment Response to Biologic Therapy in Severe Asthma.

Biener L, Morobeid H, Pizarro C, Kuetting D, Nickenig G, Skowasch D J Asthma Allergy. 2024; 17:1129-1140.

PMID: 39534315 PMC: 11556239. DOI: 10.2147/JAA.S474306.


Smoking Pack Years and Eustachian Tube Dysfunction.

Sharma A, MacDowell S, Punjabi N, Kejriwal S, Sharma V, Inman J OTO Open. 2024; 8(3):e166.

PMID: 38974178 PMC: 11225076. DOI: 10.1002/oto2.166.


Korean Red Ginseng suppresses emphysematous lesions induced by cigarette smoke condensate through inhibition of macrophage-driven apoptosis pathways.

Kim J, Kim J, Kim C, Jeong J, Ko J, Kim T J Ginseng Res. 2024; 48(2):181-189.

PMID: 38465217 PMC: 10920012. DOI: 10.1016/j.jgr.2023.11.001.


Serum YKL-40 Levels, Leukocyte Profiles, and Acute Exacerbations of Advanced COPD.

Popetiu R, Donath-Miklos I, Borta S, Rus L, Vilcea A, Nica D J Clin Med. 2023; 12(18).

PMID: 37763047 PMC: 10532402. DOI: 10.3390/jcm12186106.


Serum YKL-40 Levels in Patients with Asthma or COPD: A Pilot Study.

Popetiu R, Donath-Miklos I, Borta S, Moldovan S, Pilat L, Nica D Medicina (Kaunas). 2023; 59(2).

PMID: 36837585 PMC: 9963730. DOI: 10.3390/medicina59020383.


References
1.
Tashkin D, Altose M, Connett J, Kanner R, Lee W, Wise R . Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. Am J Respir Crit Care Med. 1996; 153(6 Pt 1):1802-11. DOI: 10.1164/ajrccm.153.6.8665038. View

2.
Cosio B, Soriano J, Lopez-Campos J, Calle-Rubio M, Soler-Cataluna J, de-Torres J . Defining the Asthma-COPD Overlap Syndrome in a COPD Cohort. Chest. 2015; 149(1):45-52. DOI: 10.1378/chest.15-1055. View

3.
Leigh R, Pizzichini M, Morris M, Maltais F, Hargreave F, Pizzichini E . Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J. 2006; 27(5):964-71. DOI: 10.1183/09031936.06.00072105. View

4.
Chubachi S, Sato M, Kameyama N, Tsutsumi A, Sasaki M, Tateno H . Identification of five clusters of comorbidities in a longitudinal Japanese chronic obstructive pulmonary disease cohort. Respir Med. 2016; 117:272-9. DOI: 10.1016/j.rmed.2016.07.002. View

5.
Zaynagetdinov R, Sherrill T, Gleaves L, Hunt P, Han W, McLoed A . Chronic NF-κB activation links COPD and lung cancer through generation of an immunosuppressive microenvironment in the lungs. Oncotarget. 2016; 7(5):5470-82. PMC: 4868699. DOI: 10.18632/oncotarget.6562. View